Urology Times Innovation Celebration Video Series : Episode 17
Video
Urology Times 50 Innovations Series: β3 agonists for overactive bladder
Author(s):
Video Player is loading.
Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Ekene A. Enemchukwu, MD, MPH, discusses the development of β3 agonists for the treatment of overactive bladder (OAB). Enemchukwu is an assistant professor of urology and, by courtesy, of obstetrics and gynecology and medical director of the Stanford Pelvic Health Center, Stanford University, Palo Alto, California
Related Videos
Investigators characterize vibegron prescribing patterns for OAB
Expert outlines advantages of batteryless sacral neuromodulation device
Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
Smaller size, patient control advantages of neurostimulator for OAB
Batteryless neurostimulator found efficacious at 6-month follow-up
Colin Goudelocke, MD, on 6-month data for batteryless neurostimulator
A physical therapist’s advice for men with post-prostatectomy incontinence
William Furuyama, MD, on community factors’ influence on urinary incontinence
Investigators explore social vulnerability and urinary incontinence
Vanita Gaglani, RPT, discusses books on post-prostatectomy incontinence and prostatitis
Related Content
